Pioneering cellular medicines for women’s health

We’re developing off-the-shelf cell therapies for high-impact women’s diseases, with lead programs in ovarian cancer, triple negative breast cancer and endometriosis.

Pioneering excellence in the field of immunotherapy

Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers, endometriosis and Alzheimer’s disease. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer and beyond.

Learn more about us

Some of our partners

Latest news

Buoyant Life Sciences Sector Emerges Stronger

By Christine Filippis / December 18, 2023
BioSpectrum Asia’s cover story in its December edition reflects on the advancement and changes that have shaped the industry in...
Read More

Chimeric Antigen Receptor (CAR) – Natural Killer (NK) Cells – Looking good for cancer therapy

By Christine Filippis / November 28, 2023
As published in Drug Target Review  Professor Alan Trounson, AO Dr Huimin Cao Dr Aleta Pupovac The suitability of NK...
Read More

Rearming the body to fight cancer

By Christine Filippis / November 15, 2023
Cartherics is currently undertaking a new capital raise to initiate clinical trials for its lead allogeneic cell therapy for ovarian...
Read More